AI-Assisted CRISPR Allergy Treatment AllerCure Enters Phase III Clinical Trial: Gene Editing to Cure Food Allergies

AI-Assisted CRISPR Allergy Treatment AllerCure Enters Phase III Clinical Trial

On March 13, 2029, Swiss company CRISPR Therapeutics announced that its food allergy gene therapy AllerCure has officially entered Phase III clinical trials. In the completed Phase II trial, 174 peanut allergy patients who received a single treatment showed 87% no longer having clinical allergic reactions to peanuts within 12 months.

AllerCure's treatment principle is fundamentally different from traditional desensitization therapy. Traditional methods train the immune system to tolerate allergens through repeated micro-exposures, requiring years of treatment with unstable results. AllerCure uses AI-optimized CRISPR-Cas12a systems to directly edit the IgE antibody-coding gene regions in patient T cells and B cells, shutting down the hypersensitivity response to specific allergens at the source.

CRISPR Therapeutics Chief Medical Officer Samarth Kulkarni said: "AI played a critical role in three stages: first, the AI model precisely identified gene sites requiring editing from patient immunomics data; second, AI designed guide RNA sequences that minimize off-target effects; and finally, AI predicted optimal dosing for each patient."

The most common adverse events in the Phase II trial were injection site redness (23% incidence) and transient lymphopenia (8% incidence), all mild to moderate and self-resolving. No serious adverse events from off-target editing were observed.

AAAAI President David Stukus commented: "If the Phase III trial confirms safety and durability, AllerCure will fundamentally change the treatment paradigm for food allergies. Going from lifelong food avoidance to a one-time treatment enabling free eating — that's a qualitative leap."

The Phase III trial plans to enroll 1,200 patients across 60 global centers, covering peanut, milk, and egg allergies, with results expected in 2031.